Macquarie Group’s Nuvectis Pharma NVCT Stock Holding History

Macquarie Group’s Portfolio NVCT Stock Details NVCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-355	Closed	-$2.25K	–	1834
2024 Q2	$2.25K	Buy	+355	New	+$2.41K	﹤0.01%	1794

Other funds holding NVCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BWP

Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JMFC

J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Macquarie Group's NVCT Position: Q3 2024 in Review

Macquarie Group sold out of Nuvectis Pharma (NVCT) in Q3 2024, closing a stake of 355 shares — an estimated $2.25K sold.

Macquarie Group first reported a position in NVCT in Q2 2024 and held it in 1 quarter. The position peaked at $2.25K in Q2 2024. 31 funds tracked by Wall St. Rank hold NVCT as of Q3 2024.

Macquarie Group reported no remaining Nuvectis Pharma position as of Q3 2024 after selling out during the quarter.
Macquarie Group sold 355 Nuvectis Pharma shares in Q3 2024, an estimated $2.25K.
Macquarie Group first reported a position in Nuvectis Pharma in Q2 2024 and held it in 1 quarter.
Macquarie Group's Nuvectis Pharma position peaked at $2.25K in Q2 2024.
31 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q3 2024.

Based on Macquarie Group's 13F filing for Q3 2024, filed 14 Nov 2024.